PT3622953T - Tratamento combinado do cancro - Google Patents

Tratamento combinado do cancro

Info

Publication number
PT3622953T
PT3622953T PT192051043T PT19205104T PT3622953T PT 3622953 T PT3622953 T PT 3622953T PT 192051043 T PT192051043 T PT 192051043T PT 19205104 T PT19205104 T PT 19205104T PT 3622953 T PT3622953 T PT 3622953T
Authority
PT
Portugal
Prior art keywords
cancer
combination treatment
treatment
combination
Prior art date
Application number
PT192051043T
Other languages
English (en)
Original Assignee
Scandion Oncology As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scandion Oncology As filed Critical Scandion Oncology As
Publication of PT3622953T publication Critical patent/PT3622953T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT192051043T 2016-05-17 2017-05-17 Tratamento combinado do cancro PT3622953T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201670325 2016-05-17

Publications (1)

Publication Number Publication Date
PT3622953T true PT3622953T (pt) 2021-04-21

Family

ID=58800797

Family Applications (2)

Application Number Title Priority Date Filing Date
PT192051043T PT3622953T (pt) 2016-05-17 2017-05-17 Tratamento combinado do cancro
PT177265733T PT3458052T (pt) 2016-05-17 2017-05-17 Tratamento combinado do cancro

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT177265733T PT3458052T (pt) 2016-05-17 2017-05-17 Tratamento combinado do cancro

Country Status (18)

Country Link
US (2) US11103481B2 (pt)
EP (3) EP3854393A1 (pt)
JP (1) JP7033554B2 (pt)
CN (1) CN109475535A (pt)
AU (1) AU2017266724B2 (pt)
BR (1) BR112018073518A2 (pt)
CA (1) CA3023202A1 (pt)
CY (2) CY1122541T1 (pt)
DK (2) DK3458052T3 (pt)
ES (2) ES2870805T3 (pt)
HR (2) HRP20200076T1 (pt)
HU (2) HUE047542T2 (pt)
LT (2) LT3458052T (pt)
PL (2) PL3622953T3 (pt)
PT (2) PT3622953T (pt)
RS (2) RS59844B1 (pt)
SI (2) SI3458052T1 (pt)
WO (1) WO2017198700A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3622953T (pt) * 2016-05-17 2021-04-21 Scandion Oncology As Tratamento combinado do cancro
WO2019165158A1 (en) * 2018-02-22 2019-08-29 University Of Florida Research Foundation, Incorporated Il-6 inhibitors and methods of treatment
EP3846802A1 (en) * 2018-09-06 2021-07-14 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
WO2020079051A1 (en) 2018-10-16 2020-04-23 Scandion Oncology A/S Compounds for treatment of microbial infection
AU2022292074A1 (en) 2021-06-14 2023-12-14 Scandion Oncology A/S Combination treatments for cancer patients and methods for identifying same
EP4104834A1 (en) 2021-06-14 2022-12-21 Scandion Oncology A/S Combination treatments for cancer patients and methods for identifying same
CA3221558A1 (en) 2021-06-14 2022-12-22 Peter Michael Vestlev Methods of increasing the plasma drug exposure of anticancer agents
TW202321205A (zh) 2021-07-16 2023-06-01 丹麥商斯坎丁腫瘤公司 Sco-101的熱力穩定形式
EP4197525A1 (en) 2021-12-20 2023-06-21 Scandion Oncology A/S Combination of drugs for the treatment of cancer
CN117229258B (zh) * 2022-06-07 2024-07-19 杭州壹瑞医药科技有限公司 N-四唑基芳基脲类衍生物及其制备方法和应用
WO2023242235A1 (en) 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
WO2024013058A1 (en) 2022-07-11 2024-01-18 Scandion Oncology A/S Salts of sco-101 and methods involving salts

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
DK0977741T3 (da) 1997-04-22 2003-12-01 Neurosearch As Substituerede phenylderivater, deres fremstilling og anvendelse
EP1514867A3 (en) 1998-10-22 2005-03-23 NeuroSearch A/S Substituted phenyl derivatives, their preparation and use
IL166040A0 (en) 2002-08-01 2006-01-15 Neurosearch As Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
WO2004111017A1 (en) 2003-06-17 2004-12-23 Neurosearch A/S Diphenylurea derivatives and their use as chloride channel blockers
JP2007520525A (ja) 2004-02-04 2007-07-26 ノイロサーチ アクティーゼルスカブ 二量体のアザ環式化合物及びその使用
JP2008524158A (ja) 2004-12-17 2008-07-10 ノイロサーチ アクティーゼルスカブ カリウムチャネル活性化剤として有用なジフェニル尿素誘導体
JP2009530238A (ja) * 2006-03-14 2009-08-27 ノイロサーチ アクティーゼルスカブ ジフェニル尿素誘導体及び塩化物チャネル遮断薬又はＢＫＣａチャネル調節薬としてのその使用
JO2885B1 (en) * 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
TWI508954B (zh) * 2012-04-27 2015-11-21 Nat Defense Medical Ct 雜環融合蒽醌衍生物、其製備方法與醫藥組合物
EP2919009B1 (en) 2014-03-10 2018-09-19 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft LRRC8 proteins and protein complexes and methods for identification of channel modulators
ES2662822T3 (es) 2015-03-04 2018-04-09 Scandion Oncology A/S Derivados de 4-amino-3-fenilamino-6-fenilpirazol[3,4-d]pirimidina para uso como inhibidores de la BCRP en tratamientos terapéuticos
PT3622953T (pt) * 2016-05-17 2021-04-21 Scandion Oncology As Tratamento combinado do cancro

Also Published As

Publication number Publication date
HRP20200076T1 (hr) 2020-04-03
US11903927B2 (en) 2024-02-20
ES2770374T3 (es) 2020-07-01
DK3458052T3 (da) 2020-02-03
BR112018073518A2 (pt) 2019-03-19
EP3458052A1 (en) 2019-03-27
WO2017198700A1 (en) 2017-11-23
SI3622953T1 (sl) 2021-05-31
HUE047542T2 (hu) 2020-04-28
EP3622953B1 (en) 2021-03-17
SI3458052T1 (sl) 2020-04-30
CY1122541T1 (el) 2021-01-27
HUE053744T2 (hu) 2021-07-28
RS59844B1 (sr) 2020-02-28
DK3622953T3 (da) 2021-04-26
JP7033554B2 (ja) 2022-03-10
CN109475535A (zh) 2019-03-15
PL3622953T3 (pl) 2021-08-16
US11103481B2 (en) 2021-08-31
AU2017266724B2 (en) 2022-04-14
CY1124242T1 (el) 2022-07-22
JP2019519506A (ja) 2019-07-11
RS61786B1 (sr) 2021-06-30
EP3854393A1 (en) 2021-07-28
US20210353596A1 (en) 2021-11-18
EP3622953A1 (en) 2020-03-18
LT3458052T (lt) 2020-02-10
PT3458052T (pt) 2020-02-03
HRP20210572T1 (hr) 2021-05-14
ES2870805T3 (es) 2021-10-27
PL3458052T3 (pl) 2020-06-29
AU2017266724A1 (en) 2018-12-20
LT3622953T (lt) 2021-04-26
EP3458052B1 (en) 2019-11-06
US20190269654A1 (en) 2019-09-05
CA3023202A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
HK1247129A1 (zh) 治療癌症的聯合療法
IL261959B1 (en) Cancer treatment with tg02
HK1251475A1 (zh) 用於癌症治療的聯合療法
PT3622953T (pt) Tratamento combinado do cancro
IL259996A (en) Combinations for cancer treatment
IL265697B1 (en) Prostate cancer treatment
IL263835A (en) Exosome-guided treatment of cancer
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
GB201408297D0 (en) Treatment of cancer
HK1251794A1 (zh) 癌症治療
IL274748A (en) Improved cancer treatment
GB201417456D0 (en) Treatment of cancer
GB201622214D0 (en) treatment of cancer
GB201704287D0 (en) Treatment of cancer
GB201703857D0 (en) Treatment of cancer
GB201702565D0 (en) Treatment of cancer
GB201604621D0 (en) Treatment of cancer
GB201604293D0 (en) Treatment of cancer
GB201702139D0 (en) Methods of cancer treatment
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer